Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya Sells 83,182 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 83,182 shares of Disc Medicine stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90. Following the sale, the director now directly owns 194,209 shares in the company, valued at approximately $10,574,680.05. This trade represents a 29.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Price Performance

Disc Medicine stock traded up $0.04 during mid-day trading on Wednesday, hitting $53.93. The company’s stock had a trading volume of 539,617 shares, compared to its average volume of 361,162. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $68.86. The company has a market cap of $1.86 billion, a PE ratio of -13.55 and a beta of 0.73. The firm’s 50 day moving average is $56.62 and its 200 day moving average is $55.94.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. As a group, analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently modified their holdings of IRON. Sterling Capital Management LLC raised its holdings in shares of Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Disc Medicine in the 4th quarter worth about $40,000. Tower Research Capital LLC TRC raised its stake in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Disc Medicine during the 3rd quarter valued at about $131,000. Finally, Quantbot Technologies LP bought a new stake in shares of Disc Medicine in the 3rd quarter valued at approximately $146,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IRON shares. Wedbush restated an “outperform” rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Scotiabank increased their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, March 3rd. TD Cowen assumed coverage on Disc Medicine in a research report on Thursday, February 27th. They issued a “buy” rating for the company. Stifel Nicolaus lifted their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $89.10.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.